AKRO

AKRO - Akero Therapeutics Inc Stock Price, Fair Value and News

$54.65 
Market Closed as of 09 Dec 2025, 04:00 pm ET

AKRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKRO Price Action

AKRO RSI Chart

AKRO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AKRO Valuation

AKRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AKRO Fundamentals

AKRO Revenue

AKRO Earnings

AKRO Profitability

AKRO Investor Care

Revenue & Growth

How Akero Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202541.7M42.3M43.4M-
202428.4M34.0M36.4M38.0M
20238.9M14.0M19.1M24.2M
2022---3.9M
2021----
AKRO
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEakerotx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44